PT - JOURNAL ARTICLE AU - XAVIER FILELLA AU - DAVID TRUAN AU - JOAN ALCOVER AU - RAFAEL GUTIERREZ AU - RAFAEL MOLINA AU - FRANCISCA COCA AU - ANTONIO M. BALLESTA TI - Complexed Prostate-specific Antigen for the Detection of Prostate Cancer DP - 2004 Nov 01 TA - Anticancer Research PG - 4181--4186 VI - 24 IP - 6 4099 - http://ar.iiarjournals.org/content/24/6/4181.short 4100 - http://ar.iiarjournals.org/content/24/6/4181.full SO - Anticancer Res2004 Nov 01; 24 AB - Background: The description of a new method for the measurement of complexed prostate-specific antigen (cPSA) offers a new approach to the diagnosis of prostate cancer. Patients and Methods: We measured PSA (Hybritech and Bayer), free PSA (Hybritech) and complexed PSA (Bayer) in 72 patients with prostate cancer and 128 with benign prostate hyperplasia. Results and Conclusion: We found an increase of sensitivity using 2.5 and 7 ng/mL as cut-offs for cPSA in relation to total PSA using as cutoffs 4 and 10 ng/mL (96 and 36% vs. 92 and 35.5%). Similar differences were found for specificity (78% and 31% for cPSA vs. 73% and 29% for total PSA). Therefore, we defined a gray zone for patients with cPSA between 2.5 and 7 ng/mL for which the measurement of the free/complexed PSA ratio saves an important number of negative biopsies maintaining a higher sensitivity. Copyright© 2004 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved